» Articles » PMID: 34830068

Expression and Functionality of Connexin-Based Channels in Human Liver Cancer Cell Lines

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Nov 27
PMID 34830068
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Liver cancer cell lines are frequently used in vitro tools to test candidate anti-cancer agents as well as to elucidate mechanisms of liver carcinogenesis. Among such mechanisms is cellular communication mediated by connexin-based gap junctions. The present study investigated changes in connexin expression and gap junction functionality in liver cancer in vitro. For this purpose, seven human liver cancer cell lines, as well as primary human hepatocytes, were subjected to connexin and gap junction analysis at the transcriptional, translational and activity level. Real-time quantitative reverse transcription polymerase chain reaction analysis showed enhanced expression of connexin43 in the majority of liver cancer cell lines at the expense of connexin32 and connexin26. Some of these changes were paralleled at the protein level, as evidenced by immunoblot analysis and in situ immunocytochemistry. Gap junctional intercellular communication, assessed by the scrape loading/dye transfer assay, was generally low in all liver cancer cell lines. Collectively, these results provide a full scenario of modifications in hepatocyte connexin production and gap junction activity in cultured liver cancer cell lines. The findings may be valuable for the selection of neoplastic hepatocytes for future mechanistic investigation and testing of anti-cancer drugs that target connexins and their channels.

Citing Articles

Understanding the Role of Connexins in Hepatocellular Carcinoma: Molecular and Prognostic Implications.

Papadakos S, Chatzikalil E, Arvanitakis K, Vakadaris G, Stergiou I, Koutsompina M Cancers (Basel). 2024; 16(8).

PMID: 38672615 PMC: 11048329. DOI: 10.3390/cancers16081533.


Influence of C Nanofilm on the Expression of Selected Markers of Mesenchymal-Epithelial Transition in Hepatocellular Carcinoma.

Sosnowska M, Kutwin M, Zawadzka K, Pruchniewski M, Strojny B, Bujalska Z Cancers (Basel). 2023; 15(23).

PMID: 38067256 PMC: 10705132. DOI: 10.3390/cancers15235553.


Polyhydroxylated Fullerene C(OH) Nanofilms Promote the Mesenchymal-Epithelial Transition of Human Liver Cancer Cells via the TGF-β1/Smad Pathway.

Sosnowska M, Kutwin M, Koczon P, Chwalibog A, Sawosz E J Inflamm Res. 2023; 16:3739-3761.

PMID: 37663761 PMC: 10474868. DOI: 10.2147/JIR.S415378.


The Multifaceted Role of Connexins in Tumor Microenvironment Initiation and Maintenance.

Kutova O, Pospelov A, Balalaeva I Biology (Basel). 2023; 12(2).

PMID: 36829482 PMC: 9953436. DOI: 10.3390/biology12020204.


The prognostic value and biological significance of gap junction beta protein 2 (GJB2 or Cx26) in cervical cancer.

Meng S, Liu Y, Wang X, Wu X, Xie W, Kang X Front Oncol. 2022; 12:907960.

PMID: 35936685 PMC: 9355537. DOI: 10.3389/fonc.2022.907960.

References
1.
Kato H, Naiki-Ito A, Naiki T, Suzuki S, Yamashita Y, Sato S . Connexin 32 dysfunction promotes ethanol-related hepatocarcinogenesis via activation of Dusp1-Erk axis. Oncotarget. 2015; 7(2):2009-21. PMC: 4811513. DOI: 10.18632/oncotarget.6511. View

2.
Wilgenbus K, Kirkpatrick C, Knuechel R, Willecke K, Traub O . Expression of Cx26, Cx32 and Cx43 gap junction proteins in normal and neoplastic human tissues. Int J Cancer. 1992; 51(4):522-9. DOI: 10.1002/ijc.2910510404. View

3.
Kawasaki Y, Kubomoto A, Yamasaki H . Control of intracellular localization and function of Cx43 by SEMA3F. J Membr Biol. 2007; 217(1-3):53-61. DOI: 10.1007/s00232-007-9051-y. View

4.
Oyamada M, Oyamada Y, Takamatsu T . Regulation of connexin expression. Biochim Biophys Acta. 2005; 1719(1-2):6-23. DOI: 10.1016/j.bbamem.2005.11.002. View

5.
Nelson L, Morgan K, Treskes P, Samuel K, Henderson C, LeBled C . Human Hepatic HepaRG Cells Maintain an Organotypic Phenotype with High Intrinsic CYP450 Activity/Metabolism and Significantly Outperform Standard HepG2/C3A Cells for Pharmaceutical and Therapeutic Applications. Basic Clin Pharmacol Toxicol. 2016; 120(1):30-37. PMC: 5225883. DOI: 10.1111/bcpt.12631. View